Literature DB >> 15308570

Thirty years of hemophilia treatment in the Netherlands, 1972-2001.

Iris Plug1, Johanna G van der Bom, Marjolein Peters, Evelien P Mauser-Bunschoten, Arja de Goede-Bolder, Lily Heijnen, Cees Smit, Jeannette E F Zwart-van Rijkom, José Willemse, Frits R Rosendaal.   

Abstract

Since the introduction of replacement therapy in the early 1960s by the infusion of plasma-derived factor VIII and IX preparations, important changes have occurred for hemophilia patients. We studied the medical and social developments over 30 years of hemophilia treatment. Since 1972, 5 cross-sectional national postal surveys among all hemophilia patients in the Netherlands were performed, the latest in 2001. The prestructured questionnaires included items on treatment, the presence of inhibitory antibodies against factor VIII or IX, the annual number of bleeding episodes, use of inpatient hospital care, and hepatitis C and HIV infections. Response rate in 2001 was 70%. Young patients (<16 years) with severe hemophilia showed the largest increase in use of prophylaxis, from 34% in 1972 to 86% in 2001. The occurrence of hemorrhages has gradually decreased. Hospital admissions decreased from 47% of all patients in 1972 to 18% in 2001. Our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in a decrease in bleeding frequency and an improvement of the medical and social circumstances of patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308570     DOI: 10.1182/blood-2004-05-2008

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

2.  Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.

Authors:  Lusine Abrahamyan; Andrew R Willan; Joseph Beyene; Marjorie Mclimont; Victor Blanchette; Brian M Feldman
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

3.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers.

Authors:  Teddy Novais; Antoine Duclos; Remi Varin; Isabelle Lopez; Valérie Chamouard
Journal:  Int J Clin Pharm       Date:  2016-02

5.  Reply to: The importance and challenge of pediatric trials of hemophilia drugs.

Authors:  Flora Peyvandi; Frits R Rosendaal; Brian O'Mahony; Pier Mannuccio Mannucci
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

6.  Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.

Authors:  Yubin Kang; Litao Xie; Diane Thi Tran; Colleen S Stein; Melissa Hickey; Beverly L Davidson; Paul B McCray
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

7.  Quality of haemophilia care in The Netherlands: new standards for optimal care.

Authors:  Frank W G Leebeek; Kathelijn Fischer
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

8.  Outcome in moderate haemophilia.

Authors:  Ingrid den Uijl; Douwe Biesma; Diederick Grobbee; Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-11-20       Impact factor: 3.443

Review 9.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

Review 10.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.